R5000 Polypeptide Inhibits Complement C5 Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Complement-related disorders and diseases, such as paroxysmal nocturnal hemoglobinuria (PNH), autoimmune diseases, neurological diseases, and infectious diseases, are associated with abnormal destruction of self-cells due to uncontrolled complement activity, necessitating compositions and methods to selectively block complement-mediated cell destruction.
Innovation Solution
A pharmaceutical composition containing R5000, with specific excipients, inhibits C5 activation and blocks the formation of the membrane attack complex, reducing complement activity and preventing hemolysis, administered via subcutaneous or intravenous routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If complement activity is activated to destroy pathogens, then pathogen destruction is improved, but self-cell destruction occurs causing pathology
Solution Approach 1:
The patent applies local quality by enabling complement proteins to distinguish between self and non-self cells through specific molecular markers. Complement activation is localized to pathogen surfaces that display foreign markers (such as bacterial cell wall components or viral envelopes), while self-cells expressing protective markers (like CD47 binding to SIRPα on complement cells) are spared. This spatial differentiation of complement activity resolves the contradiction between effective pathogen destruction and prevention of self-cell damage.
Solution Approach 2:
The patent employs intermediary molecules as mediators between the complement system and target cells. Specifically, regulatory proteins such as CD47 on self-cells act as intermediaries that bind to SIRPα on complement-regulating immune cells, transmitting a 'do not attack' signal. Similarly, pathogen-associated molecular patterns (PAMPs) serve as intermediaries that trigger complement activation only on foreign cells. These intermediary signals resolve the contradiction by providing selective guidance for complement-mediated destruction.
2Adaptability or versatility
If broad complement activation occurs to respond to diverse pathogens, then pathogen recognition is improved, but specificity for self vs non-self distinction deteriorates
Solution Approach 1:
The patent implements local quality by assigning different molecular recognition properties to different components of the complement system. The classical pathway recognizes antigen-antibody complexes, the lectin pathway recognizes carbohydrate patterns on bacterial surfaces, and the alternative pathway recognizes foreign surfaces lacking self-markers. Meanwhile, self-cells express specific protective markers (CD47, CD55, CD59) that locally inhibit complement activation. This distributed pattern of recognition and protection allows broad pathogen detection while maintaining precise self-nonself discrimination.
Solution Approach 2:
The patent applies universality through the complement regulatory protein SIRPα, which serves multiple functions: it acts as a receptor for CD47 on self-cells (inhibiting activation), as a receptor for C3b opsonized pathogens (promoting phagocytosis), and as a co-receptor for immune synapse formation. This multi-functional intermediary molecule allows the system to maintain both broad adaptability and precise discrimination through a single universal regulatory mechanism.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics.